Cell line · CVCL_1417
Papers36
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PTTG1 drives intestinal-type gastric cancer progression via G2/M checkpoint-mediated cell-cycle reprogramming. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AXL-SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat. | Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. | Sci Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| FARP1 boosts CDC42 activity from integrin αvβ5 signaling and correlates with poor prognosis of advanced gastric cancer. | Oncogenesis | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. | Int J Cancer | 2018 | Cellosaurus cites it | PubMed | |
| A Landscape of Pharmacogenomic Interactions in Cancer. | Cell | 2016 | Cellosaurus cites it | PubMed | |
| TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. | Genome Med | 2015 | Cellosaurus cites it | PubMed | |
| A resource for cell line authentication, annotation and quality control. | Nature | 2015 | Cellosaurus cites it | PubMed | |
| A comprehensive transcriptional portrait of human cancer cell lines. | Nat Biotechnol | 2015 | Cellosaurus cites it | PubMed | |
| Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. | Sci Data | 2014 | Cellosaurus cites it | PubMed | |
| Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters. | PLoS One | 2014 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1417/papers